WO2021210490A1 - Feuille adhésive pour la peau - Google Patents

Feuille adhésive pour la peau Download PDF

Info

Publication number
WO2021210490A1
WO2021210490A1 PCT/JP2021/014918 JP2021014918W WO2021210490A1 WO 2021210490 A1 WO2021210490 A1 WO 2021210490A1 JP 2021014918 W JP2021014918 W JP 2021014918W WO 2021210490 A1 WO2021210490 A1 WO 2021210490A1
Authority
WO
WIPO (PCT)
Prior art keywords
adhesive sheet
skin
pressure
sheet
acid
Prior art date
Application number
PCT/JP2021/014918
Other languages
English (en)
Japanese (ja)
Inventor
英淑 権
田中　弘
文男 神山
Original Assignee
コスメディ製薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コスメディ製薬株式会社 filed Critical コスメディ製薬株式会社
Priority to KR1020227034996A priority Critical patent/KR20230002372A/ko
Priority to CN202180027886.7A priority patent/CN115397401A/zh
Publication of WO2021210490A1 publication Critical patent/WO2021210490A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0208—Tissues; Wipes; Patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to an adhesive sheet for skin.
  • a patch for skin application such as a poultice, a cooling sheet, a tape, etc., in which a hydrophilic external adhesive composition for skin having adhesiveness on a support is spread, has been developed.
  • a preparation is required to be in close contact with the skin for a predetermined time without peeling, and it is also important to stably disperse or dissolve the drug in the pressure-sensitive adhesive layer.
  • a transdermal absorbable preparation consisting of polyacrylic acid having a 10% aqueous solution viscosity of 100 to 1000 cps, a water-soluble polymer, polyhydric alcohol, and water (Patent Document 2).
  • Patent Document 3 N-vinylacetamide / sodium acrylate copolymer, water-soluble aluminum salt, water-containing gel patch consisting of water
  • Patent Document 4 poultice to which polybutene and gelatin are added
  • the conventional hydrophilic pressure-sensitive adhesive composition and the hydrophilic patch have problems such as insufficient adhesive strength and difficulty in practical use.
  • Japanese Unexamined Patent Publication No. 60-226808 Japanese Unexamined Patent Publication No. 6-135828 Japanese Unexamined Patent Publication No. 9-143060 Japanese Unexamined Patent Publication No. 9-208462
  • An object of the present invention is to improve the solubility of the above-mentioned acrylic copolymer in a hydrophilic medium and the adhesive strength to the skin. That is, it is an object of the present invention to provide an adhesive sheet for skin using an acrylic copolymer which has sufficient adhesive strength, can stably dissolve or uniformly disperse a drug, and has excellent solubility in a hydrophilic medium. ..
  • alkyl acrylate copolymer ammonium alkyl acrylate / vinyl acetate copolymer
  • styrene / alkyl acrylate copolymer ammonium we have found that by using an adhesive, an adhesive sheet for skin having excellent adhesive strength to the skin and a good feeling of use and capable of stably dissolving or uniformly dispersing the drug can be obtained, and the present invention has been completed. I arrived.
  • the present invention is as shown below.
  • An adhesive sheet for skin containing an adhesive layer containing an acrylic resin having a "hardness” of 2.0 or less and / or an "IR strength ratio” of 2.0 or more.
  • the acrylic resin is at least one selected from the group consisting of alkyl acrylate copolymer ammonium, alkyl acrylate / vinyl acetate copolymer and styrene / alkyl acrylate copolymer ammonium.
  • the adhesive sheet for skin of the present invention has strong adhesive strength and is excellent in stable solubility or uniform dispersibility of drugs and the like.
  • Adhesive / Adhesive Layer As the adhesive layer in the present invention, an adhesive sheet prepared by using a commercially available adhesive can be used. Rubber-based adhesives are not preferable because they have low water vapor permeability and tend to accumulate sweat and cause skin irritation in summer. Silicone adhesives generally have low adhesiveness and may cause inconvenience in use. An acrylic pressure-sensitive adhesive is preferable in consideration of adhesion to the skin and adhesion to the support film.
  • the adhesive layer is exemplified by 10 ⁇ m to 800 ⁇ m. In particular, in the case of application to the skin, 50 ⁇ m to 500 ⁇ m is preferable, and 100 ⁇ m to 300 ⁇ m is more desirable in order to improve the usability.
  • these pressure-sensitive adhesives may be used by using one kind of pressure-sensitive adhesive as a sheet, but may also be used by laminating the pressure-sensitive adhesive on several layers.
  • a sheet with a thickness of 3 mm was prepared from several types of acrylic resin, and a stainless steel cylinder with a diameter of 1.5 mm was compressed from above using a small tabletop tester EZ Test EZSX (manufactured by Shimadzu Corporation) (compression speed: 0.5 mm). / min).
  • the value of the compressive stress (N: unit) at a compressive depth of 0.1 to 0.2 mm at which a stable compressive stress is obtained on the obtained compressive stress to compressive depth curve is defined as "hardness" in the present invention. ..
  • Hardness means that a sheet with a thickness of 3 mm is prepared from acrylic resin, and a stainless steel cylinder with a diameter of 1.5 mm is compressed from the top surface of the sheet using a small tabletop tester EZ Test EZSX (manufactured by Shimadzu Corporation). The value (unit: N) of the compressive stress at a compressive depth of 0.1 to 0.2 mm in the obtained compressive stress to compressive depth curve after compression at 5 mm / min.
  • the infrared absorption spectrum of the acrylic resin was further measured to determine whether it could be used as an adhesive or as a support film.
  • the ratio of the absorption intensity of the absorption intensity and 1230 cm -1 vicinity peak of 2900 cm -1 vicinity peak (Int1230cm -1 / Int2900cm -1), hereinafter referred to as "IR intensity ratio”.
  • 1230 cm -1 is derived from C-O-C bending vibration in an acrylic ester
  • 2900 cm -1 is derived from C-H, the C-H 2 stretching vibration.
  • the acrylic resin having a hardness of 4.0 or less, preferably 3.0 or less, more preferably 2.0 or less is the acrylic in the present invention. It turned out to be suitable as an adhesive.
  • an acrylic resin having an IR strength ratio of 2.0 or more is preferable as the acrylic pressure-sensitive adhesive in the present invention.
  • Vinizol 1087FT (Acrylate Cosme Ammonium, manufactured by Daido Kasei Kogyo Co., Ltd., (Hardness: 0.2) (IR intensity ratio: 2.9)
  • Iodosol GH800 F Alkyl acrylate copolymer, Axonobel Co., Ltd.
  • MASCOS registered trademark
  • 10 adhesive acrylic ester, manufactured by Cosmed Pharmaceutical Co., Ltd., (hardness: 0.4) (IR strength) Ratio: 2.24)
  • Iodosol GH41F (Styrene / Alkyl Acrylate Copolymer Ammonium, AkzoNobel Co., Ltd. (Hardness: 8.2), (IR Strength Ratio: 1.1)) can be used for hard supports, but for adhesive applications. Is unsuitable.
  • a film made of a synthetic polymer is preferable, and it is necessary that the film has excellent adhesiveness to an acrylic pressure-sensitive adhesive, can maintain strength, and can be easily formed into a thin film.
  • Conventionally used polyolefins, PET (polyethylene terephthalate), polyvinyl alcohol, polyurethane, etc. can also be used, but in the present invention, the affinity with the acrylic pressure-sensitive adhesive is good, and therefore the adhesiveness is excellent and hard.
  • Acrylic resins can be preferably used.
  • a support sheet made of an acrylic resin having a "hardness" of 5.0 or more can be preferably used, the "hardness" is 5.0 or more, and the "IR strength ratio" is 2.
  • a support sheet made of an acrylic resin of less than 0 can be more preferably used.
  • the adhesive layer may contain skin valuables in the present invention.
  • the skin valuables are not particularly limited as long as they are valuables absorbed through the skin.
  • pigmentation inhibitor, moisturizer, metabolism activator, antioxidant, active oxygen scavenger / radical scavenger, fat metabolism promoter, anti-inflammatory agent, blood flow promoter, testosterone 5 ⁇ reductase activity inhibitor, hair examples include a papillary activator, a hair growth promoter, and the like.
  • Anti-pigmentation agent can be added to the present invention.
  • the pigmentation inhibitor include p-aminobenzoic acid derivative, sartylic acid derivative, benzenesulfonamide derivative, imidazole derivative, naphthalene derivative, hydroxyanthranic acid or a salt thereof, and their derivatives, anthranic acid derivative, coumarin derivative, and allantin.
  • Derivatives, nicotinic acid derivatives, ascorbic acid or salts thereof and derivatives thereof, tocopherols or salts thereof and derivatives thereof, and the like can be mentioned.
  • moisturizers can be added to the present invention.
  • moisturizers include quince seeds, agar or derivatives thereof, casein, glucose, galactose, mannose, xylose, fructose, maltose, isomaltose, cellobiose, gentiobiose, pyrarose, 1,3-butylene glycol, glycerin, propylene glycol, etc.
  • Metabolite activator A metabolism activator can be added to the present invention.
  • Specific examples of the metabolic activator include vitamin A group: retinol or a salt thereof and a derivative thereof, retinal or a salt thereof and a derivative thereof, dehydroretinal or a salt thereof and a derivative thereof, retinoic acid or a salt thereof and a derivative thereof.
  • Vitamin C group ascorbic acid or salts thereof and their derivatives
  • Vitamin D group ergocalciferol or its salt and its derivatives
  • choleciferol and its salts and their derivatives Vitamin E group, etc .: tocopherols or salts thereof and derivatives thereof, tocotrienols or salts thereof and derivatives thereof, ubiquinone or salts thereof and derivatives thereof, linolenic acid or salts thereof and derivatives thereof, linolenic acid or salts thereof and their salts.
  • valine leucine, isoleucine, threonine, methionine, phenylalanine, tryptophan, lysine, glycine, alanine, aspartic acid, glutamine, serine, cysteine, cystine, tyrosine, proline, hydroxyproline, aspartic acid, glutamic acid, hydroxylysine, arginine.
  • Ornithine, histidine or derivatives thereof, and amino acids such as sulfates, phosphates, nitrates, citrates, or amino acid derivatives such as pyrrolidonecarboxylic acid.
  • ⁇ -Hydroxy acids such as glycolic acid, citric acid, malic acid, tartaric acid, lactic acid, succinic acid, 2-hydroxycarboxylic acids, polyhydroxycarboxylic acids or hydroxypolycarboxylic acids, lactobionic acid, photosensitizer No. 301, hinokithiol, pantothenic acid
  • a derivative thereof, allantin, trimethylglycine, proteoglycan, and the like can be mentioned.
  • Antioxidants can be added to the present invention.
  • Specific examples of antioxidants include ascorbic acid or a salt thereof and a derivative thereof, tocopherol or a salt thereof and a derivative thereof, tocotrienol or a salt thereof and a derivative thereof, butylhydroxytoluene (BHT), butylhydroxyanisole (BHA), and the like.
  • BHT butylhydroxytoluene
  • BHA butylhydroxyanisole
  • Active oxygen scavenger / radical scavenger can be added to the present invention.
  • active oxygen scavengers and radical scavengers include superoxide dismutase, catalase, glutathione peroxidase, bilirubin, quercetin, quercitrin, catechin, catechin derivatives, rutin or derivatives thereof, gallic acid or salts thereof, and derivatives thereof, curcumin.
  • Lipid metabolism promoter An lipid metabolism promoter can be added to the present invention.
  • Specific examples of fat metabolism promoters include xanthine derivatives (caffeine, theophylline, theobromine, xanthine, aminophylline, cholineteophylline, diprophylline, proxiphyllin, oxtriphyllin, etc.), cocculus orbicula extract, cocculus orbicula extract, and cocculus orbicula.
  • xanthine derivatives caffeine, theophylline, theobromine, xanthine, aminophylline, cholineteophylline, diprophylline, proxiphyllin, oxtriphyllin, etc.
  • cocculus orbicula extract cocculus orbicula extract
  • cocculus orbicula extract examples thereof include (self-defense) extract, gajutsu ( ⁇ ) extract, Karakusakeman extract,
  • Anti-inflammatory agent can be added to the present invention.
  • anti-inflammatory agents include quinolinone derivatives, dibenzooxepine derivatives, thiotroposine, phthalimide derivatives, flurubiprofen, fervinac, bufexamac, sprofene, 1,4-diphenylpropylpiperazin derivatives, carxin compounds, chromanol glycosides ( 2- ( ⁇ -D-glucopyranosyl) methyl-2,5,7,8-tetramethylchroman-6-ol), ictamol, indomethacin, kaolin, diphenhydramine hydrochloride, d-camfur, DL-camfur, salicylic acid, sodium salicylate, Methyl salicylate, acetylsalicylic acid, hydrocortisone, guaiazulene, camazulene, chlorpheniramine maleate, diphenhydramine hydrochloride, cremastine fumarate
  • Derivatives glycylic acid or salts thereof and derivatives thereof, mephenumic acid, phenylbutazone, ibprofen, ketoprofen, allantin, calcium pantothenate, pantenol such as pantothenyl ethyl ether and salts thereof and derivatives thereof, ⁇ -aminocaproic acid, Examples thereof include sodium diclofenac, salicylic acid or a derivative thereof, sulfatide, chlorpheniramine maleate, diphenhydramine hydrochloride, and the like.
  • Blood flow promoter An blood flow promoter can be added to the present invention.
  • blood flow enhancers include tocopherol or a salt thereof and a derivative thereof, tocotrienol or a salt thereof and a derivative thereof, cepharanthin, carpronium chloride, eugenol derivative, minoxidil, tincture tincture, vanylamide nonylate, cantalis tincture, ginger.
  • Tincture L-menthol, camphor, benzyl nicotinate, ictamol, ⁇ -borneol, valenylamide nonylate, capsaicin, senburi extract, garlic extract, carrot extract, gentian extract, touki extract, ginger extract, semburi (this drug) Extracts, etc. can be mentioned.
  • Testosterone 5 ⁇ -reductase activity inhibitor / hair papilla activator / hair growth promoter can be added.
  • Specific examples of testosterone 5 ⁇ reductase activity inhibitor, hair papilla activator, and hair growth promoter include ⁇ -amino- ⁇ -hydroxybutyric acid esters, amine oxides, alkyl betaines, pyrimidine-N-oxide derivatives, and acetylcarnitine.
  • a salt thereof, geranylgeranyl acetone, a hydroxamic acid derivative or a salt thereof, proanthocyanidins, and the like can be mentioned.
  • Low molecular weight component In addition to the above-mentioned components, a low molecular weight component usually used for external preparations for skin such as cosmetics and pharmaceuticals may be added to the present invention.
  • Low molecular weight components consist of one or more other aqueous components, oily components, plant extracts, animal extracts, powders, surfactants, oils, alcohols, pH adjusters, preservatives, thickeners, pigments, fragrances, etc. Consisting of ingredients, these are part of the base and can also serve as valuable resources due to their effects on the skin.
  • a surfactant having an HLB value of 3.5 or more and 12 or less is desirable.
  • HLB value is in this range, the pressure-sensitive adhesive is easily molded and the molded pressure-sensitive adhesive sheet feels good.
  • the content of the surfactant is 1% by mass or more and 20% by mass or less, preferably 2% by mass or more and 15% by mass or less with respect to the adhesive layer.
  • a polyhydric alcohol is desirable for adjusting the viscosity of the coating liquid of the pressure-sensitive adhesive, and ethylene glycol, glycerin, propylene glycol, etc. are mentioned, and glycerin is preferable.
  • the content of the polyhydric alcohol is 0.2% by mass or more and 5% by mass or less, preferably 0.5% by mass or more and 3.0% by mass or less with respect to the adhesive layer.
  • the pressure-sensitive adhesive sheet is made by adding a plasticizer, a surfactant, etc. to the main ingredient, an acrylic pressure-sensitive adhesive (obtained in a state where the acrylic polymer is suspended in water or dissolved in an organic solvent), depending on the purpose. It is added, and a solvent (water or organic solvent) is further added for homogenization to prepare a coating liquid.
  • the coating liquid is applied onto a PET release film so that the thickness after drying becomes a predetermined thickness, and dried at about 70 to 90 ° C. for about 10 minutes to obtain an adhesive sheet.
  • the support sheet can be used as it is when a polyolefin film, PET film or the like is used.
  • the support sheet is obtained by a coating method similar to that for producing an adhesive sheet.
  • the obtained pressure-sensitive adhesive sheet can independently constitute the skin pressure-sensitive adhesive sheet of the present invention.
  • a laminated sheet obtained by laminating the obtained adhesive sheet and a support sheet is also included in the skin adhesive sheet of the present invention.
  • Example 1 Adhesive sheets and support sheets were prepared and their properties were evaluated. Then, the adhesive sheet and the support sheet were laminated. Preparation of adhesive sheet Acrylic ester emulsion type adhesive (Vinizol 1087FT, Daido Kasei Kogyo Co., Ltd., Iodosol GH800F (alkyl copolymer ammonium acrylate, AkzoNobel Co., Ltd.), and isopropyl myristate (Nakalitesk Co., Ltd.) as a plasticizer ), Octyldodecyl lactate (Esterol LOD, National Mimatsu Co., Ltd.), Aronbis AH-106X and glycerin as a solution viscosity adjuster, Saracos DG-15 as an emulsifier, and a coating solution.
  • Acrylic ester emulsion type adhesive (Vinizol 1087FT, Daido Kasei Kogyo Co., Ltd., Iodosol GH800F
  • Example 1 illustrates the composition of the pressure-sensitive adhesive as Example 1-4.
  • yodozol GH41F alkyl acrylate copolymer ammonium, AkzoNobel Co., Ltd.
  • All of the above compositions showed good adhesiveness.
  • Example 1 in Table 1 The adhesive sheet of Example 1 in Table 1 and the five types of support sheets in Table 2 were laminated to obtain an adhesive sheet with a support sheet.
  • Examples 5 and 6 having a "hardness" value of 5.0 or more had high functionality as a support sheet when laminated with an adhesive sheet, but Comparative Example 1, Comparative Example 2, and Comparison In Example 3, the sheet was soft and did not function as a support sheet.
  • Table 3 summarizes the "hardness” and “IR strength ratio” of the adhesive and support used in Tables 1 and 2.
  • Cosmetic sheet for skin The adhesive sheet of the present invention is applied as a sheet for protecting facial skin, moisturizing, etc. without containing valuable skin resources in the adhesive layer.
  • Cosmetic sheet for skin The adhesive sheet of the present invention is applied as a sheet for protecting facial skin, moisturizing, whitening, promoting blood flow, etc. with skin valuables contained in the adhesive layer.
  • Cosmetic sheet for skin The adhesive sheet of the present invention is applied as an adhesive sheet for lining a microneedle array with or without skin valuables contained in the adhesive layer.
  • Table 5 shows the skin cosmetic sheet composition.
  • Example 12 VC ethylascorbic acid was used as a pigmentation inhibitor, in Example 13, trehalose was used as a moisturizer, in Example 14, tocopheryl retinoate as a metabolic activator, and in Example 15, antioxidant.
  • An example is shown.
  • the skin cosmetic sheet compositions of Examples 12 to 18 were laminated and molded on the support sheet of Example 10.
  • the composition sheets of Examples 12 to 18 laminated on the support sheet all had a good feel of a decorative sheet.
  • the adhesive sheet for skin of the present invention has an appropriate adhesiveness to the skin, and at the same time, it is possible to blend valuable skin resources, so that a cosmetic effect on the skin can be expected.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne une feuille adhésive pour la peau, qui a une force d'adhérence satisfaisante, et dans laquelle un médicament peut être dissous de manière stable ou dispersé de manière uniforme, et qui est produite à l'aide d'un copolymère acrylique ayant une excellente solubilité dans un milieu hydrophile.　La feuille adhésive pour la peau comprend une couche adhésive comprenant une résine acrylique ayant une "dureté" de 2,0 ou moins et/ou ayant "un rapport d'intensité IR " de 2,0 ou plus. La "dureté" fait référence à une valeur (unité : N) d'une contrainte de compression à une profondeur de compression de 0,1 à 0,2 mm dans une courbe (contrainte de compression)-à-(profondeur de compression), où la courbe (contrainte de compression)-à-(profondeur de compression) est produite en produisant une feuille ayant une épaisseur de 3 mm à partir d'une résine acrylique, puis en comprimant un cylindre inoxydable ayant un diamètre de 1,5 mm à partir de la surface supérieure de la feuille à un taux de compression de 0,5 mm/min à l'aide d'un testeur de table compact "EZ Test EZSX" (Shimadzu Corporation).
PCT/JP2021/014918 2020-04-13 2021-04-08 Feuille adhésive pour la peau WO2021210490A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020227034996A KR20230002372A (ko) 2020-04-13 2021-04-08 피부용 점착 시트
CN202180027886.7A CN115397401A (zh) 2020-04-13 2021-04-08 皮肤用粘合片

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020071728A JP2021167293A (ja) 2020-04-13 2020-04-13 皮膚用粘着シート
JP2020-071728 2020-04-13

Publications (1)

Publication Number Publication Date
WO2021210490A1 true WO2021210490A1 (fr) 2021-10-21

Family

ID=78080066

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/014918 WO2021210490A1 (fr) 2020-04-13 2021-04-08 Feuille adhésive pour la peau

Country Status (4)

Country Link
JP (1) JP2021167293A (fr)
KR (1) KR20230002372A (fr)
CN (1) CN115397401A (fr)
WO (1) WO2021210490A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61228868A (ja) * 1985-04-04 1986-10-13 積水化学工業株式会社 医療用粘着剤に用いられる樹脂およびそれを用いた医療用粘着シ−トもしくはテ−プ
JPS61290956A (ja) * 1985-06-18 1986-12-20 積水化学工業株式会社 医療用粘着剤に用いられる樹脂およびそれを用いた医療用粘着シ−トもしくはテ−プ
JP2005194402A (ja) * 2004-01-07 2005-07-21 Kosumedei:Kk 粘着剤組成物および貼付剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60226808A (ja) 1985-03-11 1985-11-12 Watanabe Yakuhin Kogyo Kk シツプ薬
JP3193161B2 (ja) 1992-10-23 2001-07-30 久光製薬株式会社 経皮吸収性製剤
JPH09143060A (ja) 1995-11-16 1997-06-03 Showa Denko Kk 含水ゲル貼付剤基剤用組成物
JPH09208462A (ja) 1996-02-07 1997-08-12 Tsumura & Co 自己粘着型パップ剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61228868A (ja) * 1985-04-04 1986-10-13 積水化学工業株式会社 医療用粘着剤に用いられる樹脂およびそれを用いた医療用粘着シ−トもしくはテ−プ
JPS61290956A (ja) * 1985-06-18 1986-12-20 積水化学工業株式会社 医療用粘着剤に用いられる樹脂およびそれを用いた医療用粘着シ−トもしくはテ−プ
JP2005194402A (ja) * 2004-01-07 2005-07-21 Kosumedei:Kk 粘着剤組成物および貼付剤

Also Published As

Publication number Publication date
KR20230002372A (ko) 2023-01-05
JP2021167293A (ja) 2021-10-21
CN115397401A (zh) 2022-11-25

Similar Documents

Publication Publication Date Title
EP1513889B1 (fr) Gel aqueux : procede de production et d'utilisation
JP5840107B2 (ja) ヒアルロン酸ゲル及びその製造方法
US10639266B2 (en) Water-soluble hyaluronic acid gel and method for producing same
TWI392515B (zh) Skin topical composition
JP2005139070A (ja) 皮膚化粧料
JP4809161B2 (ja) 皮膚外用剤
CN109069393B (zh) 化妆用醇凝胶膜及其制造方法
JP6975516B2 (ja) 外用組成物、化粧料、経皮吸収促進用組成物、外用組成物における有効成分の経皮吸収性を高める方法、経皮投与型医薬及び点眼用組成物
WO2021201266A1 (fr) Micro-aiguille à dissolution rapide
JP4693340B2 (ja) 含水ゲル体、該含水ゲル体の製造方法およびその用途
JP2008285461A (ja) 生体用粘着ゲルシートおよびそれを含むシート状化粧料
JP2009256295A (ja) 化粧用粘着シート
WO2021210490A1 (fr) Feuille adhésive pour la peau
TW201012482A (en) Thickening composition and process for production thereof
JP2005060233A (ja) 皮膚外用剤
JP2004123575A (ja) 外用ゲル状組成物
JP5485522B2 (ja) 乳化組成物
JP2005160890A (ja) 生体用粘着ゲルシート
JP6709585B2 (ja) 皮膚外用剤
WO2022019187A1 (fr) Préparation externe pour produit cosmétique et produit cosmétique
JP7356090B2 (ja) エイジングケア用マイクロニードル
WO2021246301A1 (fr) Réseau de micro-aiguilles pour soins esthétiques
JP6893944B2 (ja) 皮膚外用剤
JP2017039696A (ja) 化粧料
JP2012158567A (ja) 皮膚外用組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21787791

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21787791

Country of ref document: EP

Kind code of ref document: A1